Menu

Research/Reports

After Failing To Disclose Conflict of Interest, JAMA Issues Correction to Piece Calling for Increased 340B Oversight and Transparency

Bella Czajkowski, National Correspondent 340B Report Views
JAMA corrected an opinion piece on the 340B program to disclose one author's drug industry ties, shortly after 340B Report reported on the omission.
…
Read More »

Two Researchers Call For More 340B Transparency, but JAMA Fails to Disclose Glaring Conflict of Interest

Bella Czajkowski, National Correspondent 340B Report Views
Two researchers authored a recent JAMA opinion piece calling for significant 340B reforms including asking Congress to consider limiting the program to low-income patients.
…
Read More »

IRA Could ‘Crush the 340B Margin,’ Force Transparency into Program, Says Adam Fein of Drug Channels

William Newton, Editor-in-Chief 340B Report Views
Adam Fein, Ph.D., president of Drug Channels Institute, hosted a June 21 webinar that discussed the IRA's interaction with the 340B program.

The Inflation Reduction Act (IRA) may reduce 340B margins for certain high-cost drugs and drive more transparency into the program, an influential pharmaceutical supply chain analyst who has been a frequent 340B critic told an audience of stakeholders late

…
Read More »

CBO Analysts Say Drug Spending Through 340B Grew 19% Annually From 2010 to 2021, 340B Champion Points Finger at Drug Industry

Shannon Young, Managing Editor 340B Report Views
Congressional Budget Office logo
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by 2021—a 19% annual increase—according to preliminary Congressional Budget Office estimates released this week.
…
Read More »

340B Reform Could Generate Federal Savings, Says Consulting Firm That Has Conducted 340B Studies for Pharma Friendly Groups

Rich Daly, Editor in Chief 340B Report Views
Avalere's Milena Sullivan told 340B Report that it's important to understand "the impact 340B reform could have on federal spending."
…
Read More »

340B Hospitals Prescribe Part D Drugs to a Much Higher Share of Vulnerable Populations, Says Hospital-Backed Report

Shannon Young, Managing Editor 340B Report Views
A hospital-funded study found 340B hospitals prescribe a higher share of Medicare Part D drugs to a higher share of vulnerable patients.
…
Read More »

340B Drugs Reach 18% of Outpatient Drug Sales, Says PhRMA-Backed Research; Providers Say It is Misleading

Rich Daly, Editor in Chief 340B Report Views
A PhRMA funded report found that 340B drugs grew to 18% of total outpatient branded drug sales in 2022. The figures were criticized by 340B providers and others as misleading.
…
Read More »

Study Finds Newer 340B Public Hospitals More Likely to Increase Unprofitable Service Lines Than Newer Non-Profit Hospitals

Shannon Young, Managing Editor 340B Report Views
Government-owned 340B hospitals recently enrolled in 340B were more likely to increase unprofitable services than new 340B nonprofit hospitals, a recent study found.
…
Read More »

Site Footer Live